Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin A M Gale

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Lancet (London, England)|November 25, 2010
Intensified glucose control in type 2 diabetes--whose agenda?John S Yudkin, Bernd Richter, Edwin A M Gale
Diabetes Care|November 25, 2003
Why can't we prevent type 1 diabetes?: maybe it's time to try a different combinationDesmond Schatz, Edwin A M Gale, Mark A Atkinson
Diabetologia|March 11, 2022
The insulin market reaches 100David Beran, Edwin A M Gale, John S Yudkin
Lancet (London, England)|November 2, 2010
Intensive treatment of hyperglycaemia: what are the objectives?John S Yudkin, Bernd Richter, Edwin A M Gale
Diabetes Care|October 26, 2007
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)Polly J Bingley, Jeffrey L Mahon, Edwin A M Gale, et al.
Diabetes|January 5, 2002
High familial risk and genetic susceptibility in early onset childhood diabetesKathleen M Gillespie, Edwin A M Gale, Polly J Bingley
BMJ (Clinical Research Ed.)|July 3, 2015
Productivity of authors in the field of diabetes: bibliographic analysis of trial publicationsFrits Holleman, Mick Uijldert, Lennart F Donswijk, et al.
Diabetes Care|May 7, 2013
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Peter C Butler, Michael Elashoff, Robert Elashoff, et al.
Lancet (London, England)|January 31, 2012
ADDITION-Europe and the case for diabetes screeningJohn S Yudkin, Victor M Montori, Kasia J Lipska, et al.
Diabetes Care|September 7, 2007
Recruitment to a clinical trial improves glycemic control in patients with diabetesEdwin A M Gale, Scott D Beattie, Jinghui Hu, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Lancet (London, England)|November 25, 2010
Intensified glucose control in type 2 diabetes--whose agenda?John S Yudkin, Bernd Richter, Edwin A M Gale
Diabetes Care|November 25, 2003
Why can't we prevent type 1 diabetes?: maybe it's time to try a different combinationDesmond Schatz, Edwin A M Gale, Mark A Atkinson
Diabetologia|March 11, 2022
The insulin market reaches 100David Beran, Edwin A M Gale, John S Yudkin
Lancet (London, England)|November 2, 2010
Intensive treatment of hyperglycaemia: what are the objectives?John S Yudkin, Bernd Richter, Edwin A M Gale
Diabetes Care|October 26, 2007
Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT)Polly J Bingley, Jeffrey L Mahon, Edwin A M Gale, et al.
Diabetes|January 5, 2002
High familial risk and genetic susceptibility in early onset childhood diabetesKathleen M Gillespie, Edwin A M Gale, Polly J Bingley
BMJ (Clinical Research Ed.)|July 3, 2015
Productivity of authors in the field of diabetes: bibliographic analysis of trial publicationsFrits Holleman, Mick Uijldert, Lennart F Donswijk, et al.
Diabetes Care|May 7, 2013
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?Peter C Butler, Michael Elashoff, Robert Elashoff, et al.
Lancet (London, England)|January 31, 2012
ADDITION-Europe and the case for diabetes screeningJohn S Yudkin, Victor M Montori, Kasia J Lipska, et al.
Diabetes Care|September 7, 2007
Recruitment to a clinical trial improves glycemic control in patients with diabetesEdwin A M Gale, Scott D Beattie, Jinghui Hu, et al.
Pageof 6